Antimicrobial drugs for Parkinson’s disease: Existing therapeutic strategies and novel drugs exploration
Authors:
- 27 June 2024
- journal article
- review article
- Published by Elsevier in Ageing Research Reviews
- Vol. 99, 102387
Abstract
No abstract availableKeywords
Funding Information
- National Key Laboratory Foundation of China
- National Key Research and Development Program of China (2016YFC0906300)
This publication has 101 references indexed in Scilit:
- Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthmaCell Biology and Toxicology, 2024
- Doxycycline inhibits dopaminergic neurodegeneration through upregulation of axonal and synaptic proteinsNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Stress-inducible phosphoprotein 1 (HOP/STI1/STIP1) regulates the accumulation and toxicity of α-synuclein in vivoActa Neuropathologica, 2022
- 3,4‐Dihydroxyphenylethanol and 3,4‐dihydroxyphenylacetic acid affect the aggregation process of E46K variant of α‐synuclein at different extent: Insights into the interplay between protein dynamics and catechol effectProtein Science, 2022
- Challenges of repurposing tetracyclines for the treatment of Alzheimer’s and Parkinson’s diseaseJournal of Neural Transmission, 2022
- Promising Polyphenols in Parkinson’s Disease TherapeuticsNeurochemical Research, 2020
- Microglia in Parkinson’s Disease2019
- Associations between cerebrovascular risk factors and parkinson diseaseAnnals of Neurology, 2019
- The Parkinson Pandemic—A Call to ActionJAMA Neurology, 2018
- Doxycycline restrains glia and confers neuroprotection in a 6‐OHDA Parkinson modelGlia, 2013